AlphaYou
Overview
Key stats
Fundamentals Sep 10- Open
- $221.15
- 52-wk high
- $225.80
- High
- $223.82
- 52-wk low
- $135.39
- Low
- $219.82
- Prev close
- $224.51
- Mkt cap
- $31.14B
- P/E
- 37.4x
- Volume
- 465.1K
- Fwd P/E
- 13.0x
- Beta
- 0.17
- P/S
- 3.1x
- P/B
- 1.7x
- Profit margin
- +8.3%
- Op margin
- +25.1%
- ROE
- +4.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 18.4% above what analysts expected.
Earnings per share
$3.04 expected
Reports Oct 29, 2026, in 49 days
EPS expected
$1.44 to $2.67
Revenue expected
25 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $2.45B | $2.28B | $2.48B | $2.74B |
| Cost of what it sold | $876.6M | $496.3M | $661.0M | $1.18B |
| Gross profit | $1.58B | $1.78B | $1.82B | $1.56B |
| What it spent | ||||
| Research and development | $369.6M | $509.3M | $573.0M | $495.6M |
| Sales and admin | $594.8M | $683.0M | $607.3M | $709.7M |
| Other operating costs | — | $647.7M | $239.1M | $34.0M |
| Total operating expenses | $964.4M | $1.84B | $1.42B | $1.24B |
| What was left | ||||
| Operating profit | $613.8M | -$57.0M | $397.4M | $318.1M |
| Interest on debt | $67.4M | $67.5M | $67.6M | $82.3M |
| Profit before tax | $557.3M | -$211.0M | $377.7M | $132.4M |
| Tax | $90.8M | -$162.6M | $58.2M | $34.9M |
| Net profit | $466.5M | -$48.4M | $319.5M | $97.5M |
| EBITDA | $826.9M | $212.2M | $553.6M | $78.2M |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Stifel reiterates Biogen stock rating on immunology pipeline
BullishSep 10Biogen at Wells Fargo healthcare conference: growth bets widen
BullishSep 9Watch CNBC's full interview with Wells Fargo CEO, Charlie Scharf
NeutralSep 9Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
Leans bearishSep 8Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)
BullishSep 8Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
BullishSep 4Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
NeutralSep 4Wellington Management Group LLP Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE
NeutralSep 4
Macro
20 macro signals shaping BIIB right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results